Equities analysts expect that Theravance Biopharma Inc (NASDAQ:TBPH) will post $3.71 million in sales for the current quarter, Zacks reports. Two analysts have made estimates for Theravance Biopharma’s earnings. The highest sales estimate is $4.20 million and the lowest is $3.23 million. Theravance Biopharma reported sales of $5.69 million during the same quarter last year, which indicates a negative year-over-year growth rate of 34.8%. The firm is expected to issue its next earnings report on Monday, February 26th.
According to Zacks, analysts expect that Theravance Biopharma will report full year sales of $3.71 million for the current year, with estimates ranging from $13.89 million to $14.90 million. For the next fiscal year, analysts expect that the company will post sales of $34.52 million per share, with estimates ranging from $22.93 million to $46.10 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Theravance Biopharma.
Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.05). Theravance Biopharma had a negative return on equity of 99.43% and a negative net margin of 1,604.87%.
Theravance Biopharma (TBPH) opened at $27.35 on Friday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 7.21 and a current ratio of 7.53. Theravance Biopharma has a 52 week low of $22.90 and a 52 week high of $43.44. The company has a market capitalization of $1,480.00, a price-to-earnings ratio of -5.30 and a beta of 2.09.
Hedge funds and other institutional investors have recently made changes to their positions in the company. QS Investors LLC acquired a new stake in shares of Theravance Biopharma in the second quarter valued at $100,000. Ameritas Investment Partners Inc. raised its stake in shares of Theravance Biopharma by 6.3% in the second quarter. Ameritas Investment Partners Inc. now owns 3,865 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 230 shares in the last quarter. Amalgamated Bank acquired a new stake in shares of Theravance Biopharma in the second quarter valued at $214,000. Moneta Group Investment Advisors LLC acquired a new stake in shares of Theravance Biopharma in the third quarter valued at $299,000. Finally, SG Americas Securities LLC raised its stake in shares of Theravance Biopharma by 52.8% in the third quarter. SG Americas Securities LLC now owns 9,061 shares of the biopharmaceutical company’s stock valued at $310,000 after acquiring an additional 3,130 shares in the last quarter. Institutional investors and hedge funds own 86.04% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Theravance Biopharma Inc (TBPH) Expected to Announce Quarterly Sales of $3.71 Million” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/02/09/theravance-biopharma-inc-tbph-expected-to-announce-quarterly-sales-of-3-71-million.html.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.